Published: 28. June, 2024
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation…
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation is now available from the Population Approach Group Europe (PAGE) conference in Rome, Italy. The new significant findings revealed that relative drug exposure is much higher in young children, with bioavailability decreasing with age.
- Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young children.
- Enhanced understanding of paediatric nasal drug delivery underscores the importance of agespecific considerations in nasal drug delivery.
- Efficacy of CT001 administration. solidifies the opioid-sparing advantage of the CT001 formulation, making it a safer option for paediatric patients.
Jes Trygved, CEO, Cessatech “We are very pleased with the final results and the opportunity to present them at the PAGE conference. The data strongly support our hypothesis that CT001 is highly effective in children relative to its active comparators and will be instrumental in our further development. This is a significant step towards finalizing the clinical program and making CT001 available to hospitals and the children who need approved, easy-toadminister pain relief.”
